clinical trial · NCT05581303
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
Amgen·phase3·active not recruiting·n = 7,297
Atherosclerotic Cardiovascular DiseasePlaceboOlpasiran
brief summary
The primary objective of this trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
started
Dec 14, 2022
primary completion
Mar 31, 2028
completion
Mar 31, 2028
last updated
Feb 27, 2026
official title
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol